CINCINNATI--(BUSINESS WIRE)--LIB Therapeutics Inc. (LIB), a late-stage biopharmaceutical company developing subcutaneous and oral PCSK9 inhibitor therapies for patients at very high and high-risk of ...
Privately-held drug developer LIB Therapeutics has claimed FDA approval for a new once-monthly PCSK9 inhibitor – Lerochol – that can be used to reduce cholesterol levels. The injectable product has ...
Exclusive: Ed Davey to make call ahead of 10th anniversary of Brexit vote, in strengthening of party’s position on EU ...
CINCINNATI--(BUSINESS WIRE)--LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company developing Lerodalcibep, a novel, third-generation PCSK9 inhibitor for patients at very ...
CINCINNATI, May 11, 2026--(BUSINESS WIRE)--LIB Therapeutics Inc. (LIB), a privately held biopharmaceutical company, today announced the U.S. commercial launch of LEROCHOL® (lerodalcibep-liga) ...
The FDA has greenlighted LIB Therapeutics' third-generation PCSK9 inhibitor, Lerochol, which lowers LDL-C cholesterol and has a convenience edge over its PCSK9 ...
Lib Dem leader Sir Ed Davey is calling for more investment in the NHS Liberal Democrat leader Ed Davey is urging the Labour government to “invest more in the NHS or accept continued decline”. Sir Ed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results